ARTICLE | Clinical News

SCIO-469: SCIO began a U.K. double-blind, placebo-controlled Phase Ib trial in 20 healthy volunteers to assess multiple oral doses of SCIO-469 given over two we

February 12, 2001 8:00 AM UTC

Scios Inc. (SCIO), Sunnyvale, Calif. Product: SCIO-469 Business: Autoimmune/Inflammation Therapeutic category: Signal transduction, Cytokine production Target: p38 MAP kinase Description: Oral small m...